RBC Capital analyst Brian Abrahams downgraded aTyr Pharma (ATYR) to Sector Perform from Outperform with a price target of $1.50, down from $16, after the Phase 3 EFZO-FIT trial failed to show a significant reduction in change from baseline in mean daily oral corticosteroid dose at week 48 with efzofitimod in patients with pulmonary sarcoidosis.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- Wells Fargo downgrades aTyr Pharma on efzofitimod Phase 3 failure
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- aTyr Pharma downgraded to Equal Weight from Overweight at Wells Fargo
- aTyr Pharma downgraded to Neutral from Buy at Lucid Capital
- aTyr Pharma downgraded to Hold from Buy at JonesResearch